Literature DB >> 30484018

Chinese Herbal Medicine for Osteosarcoma in the Mouse: A Systematic Review and Meta-Analysis.

Jun-Li Chang1,2, Wen-Yi Wang1,2, Yi-Mian Li1,2, Shao-Pu Hu1,2, Min Yao1,2, Xue-Jun Cui1,2, Wen-Lan Zhi1,2, Qi Shi1,2, Yong-Jun Wang1,2, Yan-Ping Yang3,4.   

Abstract

OBJECTIVE: To summarize and critically assess the inhibitory effects of Chinese herbal medicine (CHM) on tumor volume and tumor weight for the treatment of osteosarcoma (OS) in mouse models.
METHODS: PubMed, Embase, Web of Science, China Knowledge Resource Integrated Database (CNKI), Wanfang Database, VIP Database, and Chinese BioMedical (CBM) were searched since their inception dates to March 10, 2016. Two reviewers independently selected the controlled studies estimating effects of CHM on mouse OS by administration in vivo. A pair-wise meta-analysis was performed. Twenty-five studies with adequate randomization were included in the systematic review.
RESULTS: CHM may significantly inhibit OS growth in mice, as assessed using the tumor weight [20 studies, n=443; 290 for CHM and 153 for the control: pooled mean difference (MD)=-2.90; 95% confidence interval (Cl): -3.50 to -2.31: P<0.01], tumor volume (16 studies, n=382; 257 for CHM and 125 for the control; pooled MD =-2.57; 95% Cl: -3.33 to -1.80; P<0.01) and tumor growth inhibition rate.
CONCLUSION: CHM could significantly inhibit the growth of OS in mouse models, which might be supportive for the design of preclinical and clinical trials in future.

Entities:  

Keywords:  Chinese herbal medicine; meta-analysis; mouse; osteosarcoma; systematic review; xenograft model

Mesh:

Substances:

Year:  2018        PMID: 30484018     DOI: 10.1007/s11655-018-2565-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  1 in total

1.  Bone mesenchymal stem cell therapy for ovariectomized osteoporotic rats: a systematic review and meta-analysis.

Authors:  Zhenxiong Jin; Jinman Chen; Bing Shu; Yanhua Xiao; Dezhi Tang
Journal:  BMC Musculoskelet Disord       Date:  2019-11-20       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.